¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cell adhesive matrix assay"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • bone marrow-derived cell
    °ñ¼öÀ¯·¡¼¼Æ÷
  • border cell
    °æ°è¼¼Æ÷, ¼Ó°æ°è¼¼Æ÷
  • balloon cell
    dz¼±¼¼Æ÷
  • balloon cell nevus
    dz¼±¼¼Æ÷¸ð¹Ý
  • bristle cell
    ¾ï¼¾Åм¼Æ÷, °­¸ð¼¼Æ÷
  • burr cell
    ¹«µòÅ鳯ÀûÇ÷±¸
  • ciliated cell
    ¼¶¸ð¼¼Æ÷
  • clear cell
    Åõ¸í¼¼Æ÷
  • clear cell acanthoma
    Åõ¸í¼¼Æ÷°¡½Ã¼¼Æ÷Á¾, Åõ¸í¼¼Æ÷±Ø¼¼Æ÷Á¾
  • clear cell adenocarcinoma
    Åõ¸í¼¼Æ÷»ù¾ÏÁ¾, Åõ¸í¼¼Æ÷¼±¾ÏÁ¾
  • clear cell carcinoma
    Åõ¸í¼¼Æ÷¾ÏÁ¾
  • clear cell hidradenoma
    Åõ¸í¼¼Æ÷¶¡»ùÁ¾
  • clear cell sarcoma
    Åõ¸í¼¼Æ÷À°Á¾
  • columnar cell
    ¿øÁÖ¼¼Æ÷
  • committed cell
    ¾ô¸Ç¼¼Æ÷, ¼öÀÓ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • crescent cell anemia
    Ãʽ´ÞÀûÇ÷±¸ºóÇ÷
  • helper cell activity
    µµ¿ò¼¼Æ÷´É, Á¶·Â¼¼Æ÷´É
  • islet cell adenoma
    ¼¶¼¼Æ÷»ùÁ¾
  • large cell acanthoma
    Å«¼¼Æ÷°¡½Ã¼¼Æ÷Á¾
  • red cell aplasia
    ÀûÇ÷±¸¹«Çü¼º
  • sickle cell anemia
    ³´ÀûÇ÷±¸ºóÇ÷
  • subependymal giant cell astrocytoma
    ³ú½Ç¸·¹Ø°Å´ë¼¼Æ÷º°¼¼Æ÷Á¾, »óÀÇÇϰŴ뼼Æ÷º°¼¼Æ÷Á¾
  • target cell anemia
    Ç¥ÀûÀûÇ÷±¸ºóÇ÷
  • balloon cell
    dz¼±¼¼Æ÷
  • balloon cell melanoma
    dz¼±¼¼Æ÷Èæ»öÁ¾
  • balloon cell nevus
    dz¼±¼¼Æ÷¸ð¹Ý
  • basal cell
    ¹Ù´Ú¼¼Æ÷, ±âÀú¼¼Æ÷
  • basal cell carcinoma
    ¹Ù´Ú¼¼Æ÷¾ÏÁ¾, ±âÀú¼¼Æ÷¾ÏÁ¾
  • basal cell epithelioma
    ¹Ù´Ú¼¼Æ÷»óÇÇÁ¾, ±âÀú¼¼Æ÷»óÇÇÁ¾
  • basal cell nevus
    ¹Ù´Ú¼¼Æ÷¸ð¹Ý, ±âÀú¼¼Æ÷¸ð¹Ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • Hfr cell
    °íºóµµÀçÁ¶ÇÕ¼¼Æ÷
  • Hulle cell
    ¿ÜÇǼ¼Æ÷
  • ICSH = interstitial cell stimulating hormone
    °£Áú¼¼Æ÷ÀÚ±Ø(Êàòõá¬øàí©Ð½)È£¸£¸ó.
  • ICSH=£¾interstitial cell stimulating hormone
    °£Áú¼¼Æ÷ÀÚ±ØÈ£¸£¸ó.
  • K cell
    K¼¼Æ÷, »ìÇØ¼¼Æ÷
  • LE cell
    LE¼¼Æ÷.
  • LE cell phenomenon
    LE¼¼Æ÷Çö»ó.
  • Langerhans cell
    ¶û°Ô¸£Çѽº¼¼Æ÷.
  • Langerhans cell histiocytosis
    ¶û°Ô¸£Çѽº ¼¼Æ÷ Á¶Á÷±¸Áõ
  • Langerhans cell histiocytosis
    ¶û°Ô¸£Çѽº¼¼Æ÷Á¶Á÷±¸Áõ
  • Langerhans giant cell
    ¶û±×Çѽº°Å¼¼Æ÷
  • Langhans giant cell
    ¶û±×Çѽº°Å´ë¼¼Æ÷
  • Leydig cell
    ·¹À̵ðÈ÷ ¼¼Æ÷
  • Leydig cell adenoma
    ·¹À̵ðÈ÷¼¼Æ÷¼±Á¾
  • Leydig cell tumor
    ·¹À̵ðÈ÷¼¼Æ÷Á¾¾ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • biological assay
    Àθí [¸é¿ª,°£È£,À¯Àü,¹Ì»ý,±â»ý,¹ÙÀÌ]»ý¹°ÇÐÀû °ËÁ¤(¡­ËþïÒ).
  • calcitonin assay
    Ä®½ÃÅä´ÑÃøÁ¤
  • carcinoembryonic antigen assay
    ¾Ï(¼º)¹è¾Æ¼º Ç׿øÃøÁ¤
  • clonogenic assay
    Ŭ·Ð¿ø¼º ºÐ¼®
  • clonogenic assay
    Ŭ·Ð¿ø¼ººÐ¼®
  • colony formation assay
    Áý¶ôÇü¼º´ÉÃøÁ¤
  • creatine kinase assay
    Å©·¹¾ÆÆ¾Å°³ªÁ¦ÃøÁ¤
  • diagnostic assay
    Áø´ÜÀûºÐ¼®
  • dilution assay technique
    Èñ¼®ºÐ¼®¹ý
  • enzymatic assay
    È¿¼Ò¾Æ½êÀ̼º ÃøÁ¤(¹ý).
  • enzymatic assay
    È¿¼Ò¼º(ý£áÈàõ) ÃøÁ¤(ö´ïÒ)(¹ý).
  • enzyme linked immunosorbent assay ( ELISA)
    È¿¼Ò ¸é¿ªÃøÁ¤¹ý
  • enzyme assay
    È¿¼ÒÃøÁ¤(¹ý)
  • enzyme linked immunosorbent assay (ELISA)
    È¿¼Ò¸é¿ªÃøÁ¤¹ý
  • enzyme-linked immunosorbent assay
    È¿¼Ò¿¬°ü¸é¿ªÈíÂø¹ý
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • Ciliated cell
    ¼¶¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ¼¶¸ð¼¼Æ÷
  • Apex of cell
    ¼¼Æ÷²À´ë±â
    [¿¾ ¿ë¾î] ¼¼Æ÷÷
  • Cell membrane
    ¼¼Æ÷¸·
    [¿¾ ¿ë¾î] ¼¼Æ÷¸·
  • Base of cell
    ¼¼Æ÷¹Ù´Ú
    [¿¾ ¿ë¾î] ¼¼Æ÷Àú
  • Cell organelles
    ¼¼Æ÷¼Ò±â°ü
    [¿¾ ¿ë¾î] ¼¼Æ÷¼Ò±â°ü
  • Axis of cell
    ¼¼Æ÷Ãà
    [¿¾ ¿ë¾î] ¼¼Æ÷Ãà
  • Parafollicular cell
    ¼ÒÆ÷°ç¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÆ÷¹æ¼¼Æ÷
  • Follicular cell
    ¼ÒÆ÷¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÆ÷¼¼Æ÷
  • Inner pillar cell
    ¼Ó±âµÕ¼¼Æ÷
    [¿¾ ¿ë¾î] ³»ÁÖ¼¼Æ÷
  • Inner sustentacular cell
    ¼Ó¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ³»ÁöÁÖ¼¼Æ÷
  • Inner cell mass (Embryoblast)
    ¼Ó¼¼Æ÷µ¢ÀÌ [¹èÀÚ¸ðü]
    [¿¾ ¿ë¾î] ³»¼¼Æ÷±«
  • Inner cell mass [Embryoblast]
    ¼Ó¼¼Æ÷µ¢ÀÌ [¹èÀÚ¸ðü]
    [¿¾ ¿ë¾î] ³»ºÎ¼¼Æ÷±«
  • Inner phalangeal cell
    ¼Ó¼Õ°¡¶ô¼¼Æ÷
    [¿¾ ¿ë¾î] ³»Áö»ó¼¼Æ÷
  • Medullary endocrine cell
    ¼ÓÁú³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ¼öÁú³»ºÐºñ¼¼Æ÷
  • Inner hair cell
    ¼ÓÅм¼Æ÷
    [¿¾ ¿ë¾î] ³»À¯¸ð¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • natural killer cell
    ÀÚ¿¬ »ì¼¼Æ÷(í»æÔß¯á¬øà)
  • NK cell
    NK ¼¼Æ÷(á¬øà)
  • nonpermissive cell
    ºñÇã¿ë ¼¼Æ÷(ÞªúÉé»á¬øà)
  • null cell
    ¹«Ç¥Áö¼¼Æ÷(Ùíøúò½á¬øà)
  • permanent cell strain
    ¿µ±¸¼¼Æ÷ÁÖ(çµÎùá¬øàñ»)
  • permissive cell
    Çã¿ë ¼¼Æ÷(úÉé»á¬øà)
  • photoelectric cell
    ±¤ÀüÁö(ÎÃï³ò®)
  • photovoltaic cell
    ±¤ÀüÁö (ÎÃï³ò®)
  • plaque forming cell
    ÇöóÅ© Çü¼º ¼¼Æ÷(û¡à÷á¬øà)
  • plasma cell
    ÇüÁú¼¼Æ÷(û¡òõá¬øà)
  • primed cell
    °¨ÀÛ¼¼Æ÷(ÊïíÂá¬øà)
  • productive cell
    »ý»ê ¼¼Æ÷(ßæß§á¬øà)
  • red cell agglutination
    ÀûÇ÷±¸ ÀÀÁý(îåúìϹëêó¢)
  • red cell lysis
    ÀûÇ÷±¸ ¿ëÇØ(îåúìϹéÁú°)
  • regulated secretory cell
    ÇÇÁ¶Àý(ù¬ðàï½) ºÐºñ¼¼Æ÷(ÝÂÝôá¬øà)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
ADCC cell Antibody Dependent Cellular(= Cell-Mediated) Cytotoxicity cell
HCG, hCG Human Chorionic Gonadotropin; »ç¶÷À¶¸ð¼º¼º¼±ÀÚ±ØÈ£¸£¸ó
  1. Placental Glycoprotein Hormone
&nbs...
Th cell helper T cell(= T4 cell)
Ts cell suppressor T cell(= T8 cell)
BC Bachelor of Surgery [Lat. Baccal-aureus Chirurgiae]; back care; bactericidal concentration; basal ce...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
MMP2 Matrix metalloprotease 2
MMP-1 Matrix metalloproteinase 1
MMP-7 Matrix metalloproteinase 7
MMP-8 Matrix metalloproteinase 8
MMPI matrix metalloproteinase inhibitor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • basal cell epithelioma
    ±âÀú ¼¼Æ÷ »óÇÇ ¾Ï, ±âÀú ¼¼Æ÷ »óÇÇÁ¾
    Áß³â ÀÌÈÄ¿¡ »ý±â±â ½±°í ±× ŹÝÀÌ ¾È¸é ÇǺο¡ ¹ß»ýÇÑ´Ù. Ãø»öÀÇ ¼Ò°áÀýÀÌ Áý»êÇÑ Á¾¾çÀ» Çü¼ºÇϴµ¥ ¹Ý±¸»óÀ¸·Î À¶±âÇÏ´Â °Í, ÆíÆòÇÑ ¹Ý»óÀÇ ÆÛÁü µî ¿©·¯ °¡ÁöÀÌ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î´Â ÇǺΠǥÇÇ ±âÀú ¼¼Æ÷ÀÇ Áõ½ÄÀÌ°í ¼¼Æ÷ ºÐ¿­, ÀÌÇü¼º µîÀº °ÅÀÇ ³ªÅ¸³ªÁö ¾Ê´Â´Ù.
  • basal cell hyperplasia
    ±âÀú ¼¼Æ÷ °úÇü¼º
  • basal cell nevus
    ±âÀú ¼¼Æ÷ ¸ð¹Ý
  • basal cell papilloma
    ±âÀú ¼¼Æ÷ À¯µÎÁ¾
  • basal-cell layer
    ±âÀú ¼¼Æ÷Ãþ
  • basophilic cell
    È£¿°±â¼º ¼¼Æ÷
  • basosqumaous cell acanthoma
    ±âÀú ÆíÆò ¼¼Æ÷ ±Ø¼¼Æ÷Á¾
  • benign giant cell tumor
    ¾ç¼º °Å´ë¼¼Æ÷ Á¾¾ç
    1. °ñÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. °ñÀÇ ¾ç¼º Á¾¾çÀÇ Çϳª·Î ³ë¾àÀÚ¿¡°Ô ¸¹À¸¸ç ¹ß»ý ºÎÀ§´Â Àå°ü°ñÀÇ °ñ´Ü¿¡ ¸¹ÀÌ ³ªÅ¸³­´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¿øÇü, ¹æÃßÇüÀÌ ÀÖ´Ù. ¼¼Æ÷ »çÀÌ¿¡ ÆÄ°ñ¼¼Æ÷¿Í À¯»çÇÑ °Å´ë¼¼Æ÷°¡ È¥ÀçÇÑ´Ù. 2. °ÇÃÊÀÇ ¾ç¼º °Å´ë¼¼Æ÷Á¾. º»·¡ Á¾¾çÀÌ ¾Æ´Ï¸ç, °áÁ¤¼º °ÇÃÊ¿°À» °¡¸®Å°¸ç °ÇÃÊÀÇ ¼¶À¯¼º Á¶Á÷±¸Á¾¿¡ Æ÷ÇԵȴÙ.
  • beta cell tumor
    º£Å¸ ¼¼Æ÷Á¾
  • beta-cell tumor
    º£Å¸ ¼¼Æ÷ Á¾¾ç
    µµ¼¼Æ÷ Á¾¾ç Áß °¡Àå ÈçÇÑ Áúº´À¸·Î Àν¶¸° °ú´Ù ºÐºñ°¡ ÀϾ´Ù.
  • bipolar cell
    µÎ ±Ù ½Å°æ¼¼Æ÷, ½Ö±Ø ¼¼Æ÷
    µÎ °³ÀÇ µ¹±â¸¦ °¡Áø ½Å°æ¼¼Æ÷.
  • blood cell counter
    Ç÷±¸ °è¼ö±â
  • bone cell
    °ñ ¼¼Æ÷
    °ñÁ¶Á÷ÀÇ ±âº» ¼¼Æ÷. °ñ Á¶Á÷¿¡´Â µüµüÇÑ °ñ ±âÁú¾È¿¡ °ñ¼Ò°­À̶ó°í ÇÏ´Â Æ´ÀÌ ±ºµ¥±ºµ¥ ÀÖ°í, ±× ¼Ó¿¡ 1°³¾¿ÀÇ °ñ ¼¼Æ÷°¡ µé¾î ÀÖ´Ù. °ñ ¼¼Æ÷ÀÇ ÇüÅ´ °ñ¼Ò°­°ú ÀÏÄ¡ÇÏ¿© ÆíÆòÇÑ Å¸¿øÇüÀ¸·Î, ±æÀÌ´Â 15¡­27 ¥ìmÀÌ´Ù. °ñ ¼¼Æ÷´Â ´Ù¼öÀÇ °¡´Â ¿øÇüÁú µ¹±â°¡ À־, À̰ÍÀÌ ±âÁú ³»ÀÇ °ñ ¼¼°üÀ» ÅëÇÏ¿© °¡±îÀÌ ÀÖ´Â °ñ ¼¼Æ÷ÀÇ µ¹±â¿Í ÇÕÄ£´Ù. °ñ ¼¼Æ÷´Â º»·¡ °áÇÕÁ¶Á÷ÀÇ ¼¶À¯¾Æ¼¼Æ÷¿¡¼­ Çü¼ºµÇ´Â °ÍÀ¸·Î, ¸ÕÀú °ñ¾Æ¼¼Æ÷°¡ µÇ¾î, À̰ÍÀÌ ±âÁúÀ» ¸¸µé°í ÀÚ½ÅÀº ±× ±âÁú ¼Ó¿¡ µé¾î°¡ °ñ¼¼Æ÷·Î µÈ´Ù. À̰ÍÀº °ñ Á¶Á÷ÀÇ Á¦Á¶ÀÚÀ̸ç, ¼¼Æ÷ÁúÀº ¹Ì·®ÀÇ ¹ÌÅäÄܵ帮¾Æ¸¦ Æ÷ÇÔÇϰí, È£¾à¿°±â¼ºÀ» ³ªÅ¸³½´Ù.
  • bone marrow cell
    °ñ¼ö ¼¼Æ÷
  • bristle cell
    °­¸ð ¼¼Æ÷, ¸ð¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
factor v assay A test used to measure the activity of a blood clotting factor V. This test may be used to evaluate excessive bleeding. Abnormally low factor V assays may be seen in the following conditions: congenital deficiency of factor V, DIC, heparin administration, cirrhosis and primary fibrinolysis.
(27 Sep 1997)
factor vii assay A test used to measure the activity of a blood clotting factor VII. This test may be used to evaluate excessive bleeding. Abnormally low factor VII assays may be seen in the following conditions: congenital deficiency of factor VII, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration.
(27 Sep 1997)
factor viii assay A test used to measure the activity of a blood clotting factor VIII (Von Willebrand factor). This test is usually used to monitor treatment of haemophilia. Abnormally low factor VIII assays may be seen in the following conditions: congenital deficiency of factor VIII (haemophilia), DIC and secondary fibrinolysis. This test may also be performed in the evaluation of Von Willebrand's disease.
(27 Sep 1997)
factor x assay A test used to measure the activity of a blood clotting factor X. This test may be used to evaluate excessive bleeding. Abnormally low factor X assays may be seen in the following conditions: congenital deficiency of factor X, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration.
(27 Sep 1997)
factor xii assay A test used to measure the activity of a blood clotting factor XII. This test may be used to evaluate excessive bleeding. Low factor XII may be seen in cases of congenital deficiency of factor XII, heparin administration and liver disease.
(27 Sep 1997)
Farr type assay <investigation> Method of radioimmunoassay in which free antigen remains soluble and antibody antigen complexes are precipitated.
(18 Nov 1997)
17-ketogenic steroid assay test A colourimetric test, based on the Zimmermann reaction, which indicates metabolites or adrenal and testicular steroids excreted as 17-ketones in the urine; increased values are most striking in adrenocortical tumours, decreased values in Addison's disease or in panhypopituitarism.
Synonym: ketogenic corticoids test.
(05 Mar 2000)
focus-forming assay <investigation> A lab technique used to find out if a particular piece of DNA contains oncogenes (genes which are associated with cancer).
This is done by putting the DNA into animal cells which normally show contact inhibition, or which stop growing when they come into physical contact with other cells or reach a certain density in the culture.
If the cells lose contact inhibition and form areas of densely-packed cells (called foci) after receiving the DNA, it means that the DNA did contain oncogenes.
(05 Jan 1997)
leukocyte adherence assay test A test to detect the ability of leukocytes to adhere to bacteria, performed in vitro using nylon fibres to measure adherence.
(05 Mar 2000)
leukocyte bactericidal assay test A test of leukocytes to determine their ability to kill a culture of live bacteria.
(05 Mar 2000)
LH assay A blood test which measures the amount of luteinising hormone (LH). LH is a protein hormone that is secreted by the anterior pituitary gland. In women, a surge in LH at midcycle causes ovulation. For the next 7-10 days LH maintains the corpus luteum which synthesises progesterone. The corpus luteum disintegrates after about 10 days if fertilization does not occur. In men, LH stimulates production of testosterone by the Leydig cells in the testes. This test may be used to evaluate anovulatory bleeding, infertility, ovarian cysts and multiple endocrine neoplasia (MEN) I. Normal values in males: 7 to 24 U/L. Normal values in females: greater than 6-30 U/L. Greater than normal values can indicate: anorchia, hypogonadism, Klinefelter syndrome, menopause, ovarian failure, polycystic ovary disease, precocious puberty and Turner's syndrome. Lower than normal values can indicate hypopituitarism.
(27 Sep 1997)
Lowry-Folin assay A method for determining protein concentrations using the Folin-Ciocalteu reagent.
Synonym: Lowry-Folin assay.
(05 Mar 2000)
Lowry protein assay A method for determining protein concentrations using the Folin-Ciocalteu reagent.
Synonym: Lowry-Folin assay.
(05 Mar 2000)
T-cell-rich, B-cell lymphoma <tumour> A B-cell lymphoma in which more than 90% of the cells are of T-cell origin, masking the large cells that form the neoplastic B-cell component.
See: adult T-cell lymphoma.
(05 Mar 2000)
absorption cell A small glass chamber with parallel sides, in which absorption spectra of solutions can be obtained.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á